nach oben

Current Dermatology Reports

Erschienen in:

16.04.2019 | Photodermatology (B Adler and V DeLeo, Section Editor)

Photocutaneous Porphyrias

verfasst von: Maureen B. Poh-Fitzpatrick

Erschienen in: Current Dermatology Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Porphyrias are a group of eight uncommon-to-rare inherited or acquired metabolic disorders, each caused by enzyme dysfunction at various steps in the heme biosynthetic pathway. Photocutaneous porphyrias are a subset characterized by acute skin pain and/or chronic skin lesions as major features of disease signs and symptoms. Clinical and laboratory features, epidemiology, genetics, pathologic mechanisms, and current and future therapies of the photocutaneous porphyrias are discussed, with emphasis on information reflected in recent literature.

Recent Findings

Clinical and laboratory investigations of the last two decades have elucidated many aspects of the several porphyrias, especially in areas of genetics and genomic medicine. Published reviews, original investigations, and case reports of the last several years are too voluminous to list exhaustively; many are cited in literature referenced herein.

Summary

Recent progress in unraveling and solving enigmas posed by porphyrias suggests that newer and better approaches to their management, and possible life-altering, or even curative, therapies can be anticipated in the foreseeable future.

Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924–37. https://doi.org/10.1016/S0140-6736(09)61925-5.CrossRefPubMed

Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood. 2012;120(23):4496–504. https://doi.org/10.1182/blood-2012-05-423186.CrossRefPubMedPubMedCentral

Schulenberg-Brand D, Katugampola R, Badminton MN. The cutaneous porphyrias. Dermatol Clin. 2014;32(3):369–84. https://doi.org/10.1016/j.det.2014.03.001.CrossRef

Besur S, Hou W, Schmeltzer P, Bonkovsky HL. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014;4(4):977–1006. https://doi.org/10.3390/metabo4040977.CrossRefPubMedPubMedCentral

Ramanujam VM, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86:17–20 1–6. https://doi.org/10.1002/0471142905.hg1720s86.CrossRefPubMedPubMedCentral

Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol. 2015;39(4):412–25. https://doi.org/10.1016/j.clinre.2015.05.009.CrossRefPubMed

Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(9):862–72. https://doi.org/10.1056/NEJMra1608634.CrossRefPubMed

Yasuda M, Chen B, Desnick RJ. Recent advances on porphyria genetics: inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes. Mol Genet Metab. 2018. https://doi.org/10.1016/j.ymgme.2018.11.012.

• Ryan Caballes F, Sendi H, Bonkovsky HL. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int. 2012;32(6):880–93. https://doi.org/10.1111/j.1478-3231.2012.02794.x. Presents an overview of PCT, including the interconnected roles of iron, chronic hepatitis C infection, and hepcidin and updated management guidelines. CrossRefPubMedPubMedCentral

10.

Badenas C, To Figueras J, Phillips JD, Warby CA, Munoz C, Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet. 2009;75(4):346–53. https://doi.org/10.1111/j.1399-0004.2009.01153.x.CrossRefPubMedPubMedCentral

11.

Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci. 2002;47(2):419–26.CrossRefPubMed

12.

Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JP. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A. 2007;104(12):5079–84. https://doi.org/10.1073/pnas.0700547104.CrossRefPubMedPubMedCentral

13.

Rossi E. Hepcidin--the iron regulatory hormone. Clin Biochem Rev. 2005;26(3):47–9.PubMedPubMedCentral

14.

Ajioka RS, Phillips JD, Weiss RB, Dunn DM, Smit MW, Proll SC, et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood. 2008;112(12):4723–8. https://doi.org/10.1182/blood-2008-02-138222.CrossRefPubMedPubMedCentral

15.

Darwich E, To Figueras J, Molina-López RA, Deulofeu R, Olbina G, Westerman M, et al. Increased serum hepcidin levels in patients with porphyria cutanea tarda. J Eur Acad Dermatol Venereol. 2013;27(1):e68–74. https://doi.org/10.1111/j.1468-3083.2012.04511.x.CrossRefPubMed

16.

Fracanzani AL, Taioli E, Sampietro M, Fatta E, Bertelli C, Fiorelli G, et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35(4):498–503.CrossRefPubMed

17.

Gisbert JP, García-Buey L, Alonso A, Rubio S, Hernández A, Pajares JM, et al. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol. 2004;16(7):689–92.CrossRefPubMed

18.

Singal AK, Venkata KVR, Jampana S, Islam FU, Anderson KE. Hepatitis C treatment in patients with porphyria cutanea tarda. Am J Med Sci. 2017;353(6):523–8. https://doi.org/10.1016/j.amjms.2017.03.007.CrossRefPubMedPubMedCentral

19.

Pandya AG, Nezafati KA, Ashe-Randolph M, Yalamanchili R. Deferasirox for porphyria cutanea tarda: a pilot study. Arch Dermatol. 2012;148(8):898–901. https://doi.org/10.1001/archdermatol.2012.807.CrossRefPubMed

20.

Toback AC, Sassa S, Poh-Fitzpatrick MB, Schechter J, Zaider E, Harber LC, et al. Hepatoerythropoietic porphyria: clinical, biochemical, and enzymatic studies in a three-generation family lineage. N Engl J Med. 1987;316(11):645–50. https://doi.org/10.1056/NEJM198703123161101.CrossRefPubMed

21.

Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the ‘Royal Malady’. J Clin Pathol. 2012;65(3):200–5. https://doi.org/10.1136/jclinpath-2011-200276.CrossRefPubMed

22.

Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849–57. https://doi.org/10.1007/s10545-012-9544-4.CrossRefPubMed

23.

Singal AK, Anderson KE. Variegate Porphyria. 2013 Feb 14. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK121283/. Accessed Jan 2019.

24.

Hift RJ, Davidson BP, van der Hooft C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem. 2004;50(5):915–23. https://doi.org/10.1373/clinchem.2003.025213.CrossRefPubMed

25.

Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439–50.CrossRefPubMed

26.

Stein P, Badminton M, Barth J, Rees D, Stewart MF. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50(Pt 3):217–23. https://doi.org/10.1177/0004563212474555.CrossRefPubMed

27.

•• Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol. 2017;176(4):527–38. https://doi.org/10.1111/bjh.14459. An overview of all acute hepatic porphyrias, including a schematic of the heme pathway showing sites of deficient enzyme activity associated with each porphyria, a diagnostic algorithm, and treatment guidelines applicable to VP and HCP. CrossRefPubMed

28.

Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell D, Bonkovsky HL, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66(4):1314–22. https://doi.org/10.1002/hep.29313.CrossRefPubMed

29.

Stojeba N, Meyer C, Jeanpierre C, Perrot F, Hirth C, Pottecher T, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl. 2004;10(7):935–8. https://doi.org/10.1002/lt.20136.CrossRefPubMed

30.

Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, Tyblewski W, Poblete-Gutiérrez P, Minder EI, et al. Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol. 2010;90(5):512–5. https://doi.org/10.2340/00015555-0870.CrossRefPubMed

31.

Luvai A, Mbagaya W, Narayanan D, Degg T, Toogood G, Wyatt JI, et al. Hepatocellular carcinoma in variegate porphyria: a case report and literature review. Ann Clin Biochem. 2015;52(Pt 3):407–12. https://doi.org/10.1177/0004563214557568.CrossRefPubMed

32.

Wang B, Bissell DM. Hereditary Coproporphyria. 2012 Dec 13. In: Adam MP, Ardinger HH, Pagon R, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK114807/. Accessed Jan 2019.

33.

• Pallet N, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J. 2018;11(2):191–7. https://doi.org/10.1093/ckj/sfx146. Summarizes the complex interactions of renal physiology and pathology with porphyrias, emphasizing their underestimated importance. CrossRefPubMedPubMedCentral

34.

Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol. 2012;65(11):976–80. https://doi.org/10.1136/jclinpath-2012-200791.CrossRefPubMed

35.

Peoc’h K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, et al. Hepatocellular carcinoma in acute hepatic porphyrias: a Damocles Sword. Mol Genet Metab. 2018. https://doi.org/10.1016/j.ymgme.2018.10.001.

36.

Kühnel A, Gross U, Doss MO. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem. 2000;33(6):465–73.CrossRefPubMed

37.

Willandt B, Langendonk JG, Biermann K, Meersseman W, D’Heygere F, George C, et al. Liver fibrosis associated with iron accumulation due to long-term heme-arginate treatment in acute intermittent porphyria: a case series. JIMD Rep. 2016;25:77–81. https://doi.org/10.1007/8904_2015_458.CrossRefPubMed

38.

Fontanellas A, Ávila MA, Berraondo P. Emerging therapies for acute intermittent porphyria. Expert Rev Mol Med. 2016;18:e17. https://doi.org/10.1017/erm.2016.18.CrossRefPubMed

39.

•• Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008;83(3):408–14. https://doi.org/10.1016/j.ajhg.2008.08.003. Discovery of novel mutations in the ALAS2 gene in eight families leading to recognition of a new form of protoporphyria. CrossRefPubMedPubMedCentral

40.

•• Yien YY, Ducamp S, van der Vorm LN, Kardon JR, Manceau H, Kannengiesser C, et al. Mutation in human CLPX elevates levels of δ-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proc Natl Acad Sci U S A. 2017;114(38):E8045–52. https://doi.org/10.1073/pnas.1700632114. Describes the identification and analysis of a dominant heterozygous mutation in the CLPX gene causing an EPP-like phenotype in a family, showing how impaired CLPX activity impacts heme metabolism, organismal physiology, and human health. CrossRefPubMedPubMedCentral

41.

Whitman JC, Paw BH, Chung J. The role of ClpX in erythropoietic protoporphyria. Hematol Transfus Cell Ther. 2018;40(2):182–8. https://doi.org/10.1016/j.htct.2018.03.001.CrossRefPubMedPubMedCentral

42.

Gouya L, Deybach JC, Lamoril J, Da Silva V, Beaumont C, Grandchamp B, et al. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am J Hum Genet. 1996;58(2):292–9.PubMedPubMedCentral

43.

Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Da Silva V, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet. 2002;30(1):27–8. https://doi.org/10.1038/ng809.CrossRefPubMed

44.

Gouya L, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V, Brun P, et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet. 2006;78(1):2–14. https://doi.org/10.1086/498620.CrossRefPubMed

45.

Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, Badminton MN. Molecular epidemiology of erythropoietic protoporphyria in the UK. Br J Dermatol. 2010;162(3):642–6. https://doi.org/10.1111/j.1365-2133.2010.09631.x.CrossRefPubMed

46.

Schmitt C, Ducamp S, Gouya L, Deybach JC, Puy H. Inheritance in erythropoietic protoporphyria. Pathol Biol (Paris). 2010;58(5):372–80. https://doi.org/10.1016/j.patbio.2010.01.007.CrossRef

47.

Balwani M, Doheny D, Bishop DF, Nazarenko I, Yasuda M, Dailey HA, et al. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of x-linked protoporphyria. Mol Med. 2013;19:26–35. https://doi.org/10.2119/molmed.2012.00340.CrossRefPubMedPubMedCentral

48.

Whatley SD, Mason NG, Khan M, Zamiri M, Badminton MN, Missaoui WN, et al. Autosomal recessive erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to liver disease. J Med Genet. 2004;41(8):e105. https://doi.org/10.1136/jmg.2003.016121.CrossRefPubMedPubMedCentral

49.

Holme SA, Whatley SD, Roberts AG, Anstey AV, Elder GH, Ead RD, et al. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Investig Dermatol. 2009;129(3):599–605. https://doi.org/10.1038/jid.2008.272.CrossRefPubMed

50.

Méndez M, Poblete-Gutiérrez P, Morán-Jiménez MJ, Rodriguez ME, Garrido-Astray MC, Fontanellas A, et al. A homozygous mutation in the ferrochelatase gene underlies erythropoietic protoporphyria associated with palmar keratoderma. Br J Dermatol. 2009;160(6):1330–4. https://doi.org/10.1111/j.1365-2133.2009.09084.x.CrossRefPubMed

51.

Minder EI, Schneider-Yin X, Mamet R, Horev L, Neuenschwander S, Baumer A, et al. A homoallelic FECH mutation in a patient with both erythropoietic protoporphyria and palmar keratoderma. J Eur Acad Dermatol Venereol. 2010;24(11):1349–53. https://doi.org/10.1111/j.1468-3083.2010.03640.x.CrossRefPubMed

52.

Blagojevic D, Schenk T, Haas O, Zierhofer B, Konnaris C, Trautinger F. Acquired erythropoietic protoporphyria. Ann Hematol. 2010;89(7):743–4. https://doi.org/10.1007/s00277-009-0859-7.CrossRefPubMed

53.

Sarkany RP, Ross G, Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol. 2006;155(2):464–6. https://doi.org/10.1111/j.1365-2133.2006.07318.x.CrossRefPubMed

54.

• Balwani M, Naik H, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, et al. Clinical, biochemical, and genetic characterization of North American patientJAMA Dermatols with erythropoietic protoporphyria and X-linked protoporphyria. 2017;153(8):789–96. https://doi.org/10.1001/jamadermatol.2017.1557. Clinical features, porphyrin levels, and genotypes in 187 patients with EPP and 22 with XLP are described; protoporphyrin levels correlate positively with disease severity.

55.

Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. Gut. 2007;56(7):1009–18. https://doi.org/10.1136/gut.2006.097576.CrossRefPubMedPubMedCentral

56.

• Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in the management of porphyria. Hepatology. 2014;60(3):1082–9. https://doi.org/10.1002/hep.27086. Rationales and indications for liver transplantation in several porphyrias, pre-transplant evaluations and preparations, and post-transplant management issues are presented. CrossRefPubMed

57.

Rand EB, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics. 2006;118(6):e1896–9. https://doi.org/10.1542/peds.2006-0833.CrossRefPubMed

58.

Poh-Fitzpatrick MB, Wang X, Anderson KE, Bloomer JR, Bolwell B, Lichtin AE. Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad Dermatol. 2002;46(6):861–6.CrossRefPubMed

59.

Butler DF, Ginn KF, Daniel JF, Bloomer JR, Kats A, Shreve N, et al. Bone marrow transplant for X-linked protoporphyria with severe hepatic fibrosis. Pediatr Transplant. 2015;19(4):E106–10. https://doi.org/10.1111/petr.12472.CrossRefPubMed

60.

61.

Wahlin S, Stal P, Adam R, Karam V, Porte R, Seehofer D, et al. Liver transplantation for erythropoietic protoporphyria in Europe. Liver Transpl. 2011;17(9):1021–6. https://doi.org/10.1002/lt.22341.CrossRefPubMed

62.

Windon AL, Tondon R, Singh N, Abu-Gazala S, Porter DL, Russell JE, et al. Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: a case report. Am J Transplant. 2018;18(3):745–9. https://doi.org/10.1111/ajt.14581.CrossRefPubMed

63.

Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl. 2008;14(9):1340–6. https://doi.org/10.1002/lt.21527.CrossRefPubMed

64.

Holme SA, Anstey AV, Badminton MN, Elder GH. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol. 2008;159(1):211–3. https://doi.org/10.1111/j.1365-2133.2008.08616.x.CrossRefPubMed

65.

Biewenga M, Matawlie RH, Friesema ECH, Koole-Lesuis H, Langeveld M, Wilson JHP, et al. Osteoporosis in patients with erythropoietic protoporphyria. Br J Dermatol. 2017;177(6):1693–8. https://doi.org/10.1111/bjd.15893.CrossRefPubMed

66.

Balwani M, Bloomer J, Desnick R. Porphyrias. Erythropoietic protoporphyria, autosomal recessive. 2012 Sep 27 [Updated 2017 Sep 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK100826/. Accessed Jan 2019.

67.

Bonkovsky HL, Rudnick S. Erythropoietic protoporphyria and X-linked protoporphyria. Merck Manuals Professional Version. Updated Feb 2017. Available from: https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/porphyrias/erythropoietic-protoporphyria-and-x-linked-protoporphyria. Accessed Jan 2019.

68.

Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med. 2009;360(3):306–7. https://doi.org/10.1056/NEJMc0805682.CrossRefPubMed

69.

Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009;85(6):1434–9. https://doi.org/10.1111/j.1751-1097.2009.00595.x.CrossRefPubMed

70.

• Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey A, Bissell DM, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48–59. https://doi.org/10.1056/NEJMoa1411481. Results of combined phase three clinical trials of a novel therapeutic agent indicating satisfactory efficacy was achieved and safety profiles were acceptable. CrossRefPubMedPubMedCentral

71.

Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601–12. https://doi.org/10.1111/bjd.13598.CrossRefPubMed

72.

Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood. 2007;110(12):4108–10. https://doi.org/10.1182/blood-2007-04-088120.CrossRefPubMed

73.

Bossi K, Lee J, Schmeltzer P, Holburton E, Groseclose G, Besur S, et al. Homeostasis of iron and hepcidin in erythropoietic protoporphyria. Eur J Clin Investig. 2015;45(10):1032–41. https://doi.org/10.1111/eci.12503.CrossRef

74.

Landefeld C, Kentouche K, Gruhn B, Stauch T, Rößler S, Schuppan D, et al. X-linked protoporphyria: iron supplementation improves protoporphyrin overload, liver damage and anaemia. Br J Haematol. 2016;173(3):482–4. https://doi.org/10.1111/bjh.13612.CrossRefPubMed

75.

Balwani M, Bloomer J, Desnick R. X-linked Protoporphyria. 2013 Feb 14. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993-2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK121284/. Accessed Jan 2019.

76.

•• Katugampola RP, Badminton MN, Finlay AY, Whatley S, Woolf J, Mason N, et al. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol. 2012;167(4):901–13. https://doi.org/10.1111/j.1365-2133.2012.11160.x. Comprehensively details clinical phenotypes of CEP in a large number of cases; newly reported features include acute symptoms previously considered distinctive to protoporphyrias, expanding the differential diagnosis in patients with these complaints. CrossRefPubMed

77.

Katugampola RP, Anstey AV, Finlay AY, Whatley S, Woolf J, Mason N, et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. Br J Dermatol. 2012;167(4):888–900. https://doi.org/10.1111/j.1365-2133.2012.11154.x.CrossRefPubMed

78.

Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007;109(6):2618–21. https://doi.org/10.1182/blood-2006-06-022848.CrossRefPubMedPubMedCentral

79.

• Di Pierro E, Russo R, Karakas Z, Brancaleoni V, Gambale A, Kurt I, et al. Congenital erythropoietic porphyria linked to GATA1-R216W mutation: challenges for diagnosis. Eur J Haematol. 2015;94(6):491–7. https://doi.org/10.1111/ejh.12452. Discusses effects of GATA1 mutations on the CEP phenotype and illustrates the complexities of managing its features and complications. CrossRefPubMed

80.

To Figueras J, Ducamp S, Clayton J, Badenas C, Delaby C, Ged C, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood. 2011;118(6):1443–51. https://doi.org/10.1182/blood-2011-03-342873.CrossRefPubMed

81.

Robert-Richard E, Moreau-Gaudry F, Lalanne M, Lamrissi-Garcia I, Cario-André M, Guyonnet-Dupérat V, et al. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet. 2008;82(1):113–24. https://doi.org/10.1016/j.ajhg.2007.09.007.CrossRefPubMedPubMedCentral

82.

Fortian A, González E, Castaño D, Falcon-Perez JM, Millet O. Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R. J Biol Chem. 2011;286(15):13127–33. https://doi.org/10.1074/jbc.M110.205849.CrossRefPubMedPubMedCentral

83.

Blouin JM, Duchartre Y, Costet P, Lalanne M, Ged C, Lain A, et al. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria. Proc Natl Acad Sci U S A. 2013;110(45):18238–43. https://doi.org/10.1073/pnas.1314177110.CrossRefPubMedPubMedCentral

Titel: Photocutaneous Porphyrias
verfasst von: Maureen B. Poh-Fitzpatrick
Publikationsdatum: 16.04.2019
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 2/2019
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-019-0253-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Actinic Prurigo and Hydroa Vacciniforme

Implementation of Teledermatology: Theory and Practice

Risk, Prevention, Diagnosis, and Management of Post-Operative Cutaneous Infection

Legal and Regulatory Issues with Teledermatology